ADMA Biologics (ADMA Biologics) LT-Debt-to-Total-Asset : 0.40 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is ADMA Biologics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. ADMA Biologics's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.40.

ADMA Biologics's long-term debt to total assets ratio declined from Mar. 2023 (0.45) to Mar. 2024 (0.40). It may suggest that ADMA Biologics is progressively becoming less dependent on debt to grow their business.

ADMA Biologics LT-Debt-to-Total-Asset Historical Data

The historical data trend for ADMA Biologics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADMA Biologics LT-Debt-to-Total-Asset Chart

ADMA Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.67

0.47

0.37

0.44

0.43

ADMA Biologics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.45	0.44	0.44	0.43	0.40

ADMA Biologics LT-Debt-to-Total-Asset Calculation

ADMA Biologics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	140.373	/	329.182
	=	0.43

ADMA Biologics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	140.334	/	350.875
	=	0.40

ADMA Biologics (NAS:ADMA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

ADMA Biologics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of ADMA Biologics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ADMA Biologics (ADMA Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

465 State Route 17, Ramsey, NJ, USA, 07446

Website

https://www.admabiologics.com

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.

Executives

Alison Cecily Finger	director	C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Jerrold B Grossman	director	65 COMMERCE WAY, HACKENSACK NJ 07601
Young Kwon	director	C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Bryant Fong	director	2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Adam S Grossman	director, officer: President and CEO	65 COMMERCE WAY, HACKENSACK NJ 07601
Brian Lenz	officer: EVP, CFO	65 COMMERCE WAY, HACKENSACK NJ 07601
Lawrence P. Guiheen	director	65 COMMERCE WAY, HACKENSACK NJ 07601
Martha J Demski	director	7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
James Mond	officer: CSO/CMO	65 COMMERCE WAY, HACKENSACK NJ 07601
Biotest Divestiture Trust	10 percent owner	C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Biotest Pharmaceuticals Corp	director, 10 percent owner	5800 PARK OF COMMERCE BLVD., NW, BOCA RATON FL 33487